Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected.
Ruiz-Riol M, Llano A, Ibarrondo J, Zamarreño J, Yusim K, Bach V, Mothe B, Perez-Alvarez S, Fernandez MA, Requena G, Meulbroek M, Pujol F, Leon A, Cobarsi P, Korber BT, Clotet B, Ganoza C, Sanchez J, Coll J, Brander C. Ruiz-Riol M, et al. Among authors: cobarsi p. J Infect Dis. 2015 Mar 15;211(6):936-46. doi: 10.1093/infdis/jiu534. Epub 2014 Sep 23. J Infect Dis. 2015. PMID: 25249264 Free PMC article.
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.
Rosás-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC, Carrillo J, Rodriguez C, Perez-Alvarez N, Cobarsí P, Gomez CE, Esteban M, Jímenez JL, García F, Blanco J, Martinez-Picado J, Paredes R, Brander C. Rosás-Umbert M, et al. Among authors: cobarsi p. PLoS One. 2017 Sep 27;12(9):e0184929. doi: 10.1371/journal.pone.0184929. eCollection 2017. PLoS One. 2017. PMID: 28953921 Free PMC article. Clinical Trial.
Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
Rosás-Umbert M, Llano A, Bellido R, Olvera A, Ruiz-Riol M, Rocafort M, Fernández MA, Cobarsi P, Crespo M, Dorrell L, Del Romero J, Alcami J, Paredes R, Brander C, Mothe B. Rosás-Umbert M, et al. Among authors: cobarsi p. J Virol. 2019 Feb 5;93(4):e01436-18. doi: 10.1128/JVI.01436-18. Print 2019 Feb 15. J Virol. 2019. PMID: 30487276 Free PMC article.
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, Rosas-Umbert M, Cobarsi P, Escrig R, Perez-Alvarez N, Ruiz I, Rovira C, Meulbroek M, Crook A, Borthwick N, Wee EG, Yang H, Miró JM, Dorrell L, Clotet B, Martinez-Picado J, Brander C, Hanke T. Mothe B, et al. Among authors: cobarsi p. EClinicalMedicine. 2019 Jun 5;11:65-80. doi: 10.1016/j.eclinm.2019.05.009. eCollection 2019 May-Jun. EClinicalMedicine. 2019. PMID: 31312806 Free PMC article.
Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80.
Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Morón-López S, Puertas MC, Rosas-Umbert M, Cobarsi P, Escrig R, Perez-Alvarez N, Ruiz I, Rovira C, Meulbroek M, Crook A, Borthwick N, Wee EG, Yang H, Miró JM, Dorrell L, Clotet B, Martinez-Picado J, Brander C, Hanke T; BCN 01 study group. Mothe B, et al. Among authors: cobarsi p. EClinicalMedicine. 2020 Jan 10;18:100250. doi: 10.1016/j.eclinm.2019.100250. eCollection 2020 Jan. EClinicalMedicine. 2020. PMID: 31956858 Free PMC article.
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Bailón L, Llano A, Cedeño S, Escribà T, Rosás-Umbert M, Parera M, Casadellà M, Lopez M, Pérez F, Oriol-Tordera B, Ruiz-Riol M, Coll J, Perez F, Rivero À, Leselbaum AR, McGowan I, Sengupta D, Wee EG, Hanke T, Paredes R, Alarcón-Soto Y, Clotet B, Noguera-Julian M, Brander C, Molto J, Mothe B; AELIX002 Study Group. Bailón L, et al. Nat Med. 2022 Dec;28(12):2611-2621. doi: 10.1038/s41591-022-02060-2. Epub 2022 Oct 27. Nat Med. 2022. PMID: 36302893 Clinical Trial.
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, López C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiñones C, Ramírez-Viaplana F, Reyes-Urueña J, Riveira-Muñoz E, Ruiz L, Sanz S, Sentís A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, González-Beiras C, Clotet B; BCN-PEP-CoV2 Research Group. Mitjà O, et al. N Engl J Med. 2021 Feb 4;384(5):417-427. doi: 10.1056/NEJMoa2021801. Epub 2020 Nov 24. N Engl J Med. 2021. PMID: 33289973 Free PMC article. Clinical Trial.
Oral human papillomavirus type-specific infection in HIV-infected men: a prospective cohort study among men who have sex with men and heterosexual men.
Darwich L, Cañadas MP, Videla S, Coll J, Molina-López RA, Cobarsi P, Sirera G, Clotet B; Can Ruti HIV-HPV Team. Darwich L, et al. Among authors: cobarsi p. Clin Microbiol Infect. 2014 Sep;20(9):O585-9. doi: 10.1111/1469-0691.12523. Epub 2014 Jan 21. Clin Microbiol Infect. 2014. PMID: 24382308 Free article.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
19 results